HER2-negative breast cancer

June 22, 2020June 22, 2020

Pre-Surgical Imfinzi Combo Increases Cancer Eradication Chances in Trial

News

Treating high-risk, HER2-negative breast cancer patients before surgery with the immunotherapy Imfinzi (durvalumab) plus Lynparza (olaparib) and chemotherapy increases the probability for complete cancer eradication, according to the results from a Phase ... Read more

November 5, 2018

Ibrance-Faslodex Combo Improves Survival of Advanced Breast Cancer Patients, Phase 3 Trial Shows

News

Adding Pfizer’s Ibrance (palbociclib) to standard treatment Faslodex (fulvestrant) significantly extended the survival of advanced breast cancer patients in a Phase 3 clinical trial, researchers report. Called PALOMA-3, the trial (NCT01942135) specifically ... Read more

October 19, 2018

FDA Approves Talzenna to Treat BRCA-mutated Metastatic Breast Cancer

News

The U.S. Food and Drug Administration (FDA) has approved Pfizer’s Talzenna (talazoparib) for the treatment of HER2-negative advanced breast cancer in adult patients with inherited BRCA mutations. The FDA also stated that patients’ eligibility for ... Read more

January 15, 2018

FDA Approves Lynparza to Treat BRCA-mutated Metastatic Breast Cancer

News

The U.S. Food and Drug Administration (FDA) has approved Lynparza (olaparib) for a difficult-to-treat form of metastatic breast cancer. Patients with BRCA-mutated, HER2-negative breast cancer who have previously been treated ... Read more

October 13, 2017

First Breast Cancer Patient in Japanese Trial Receives Entinostat

News

The first patient has been dosed in a pivotal Phase 2 clinical trial in Japan evaluating entinostat as a therapy for hard-to-treat breast cancers. Syndax Pharmaceuticals, which developed the therapy, said the trial (NCT03291886) ... Read more

September 22, 2017September 22, 2017

Taselisib-Femara Combo Improves Response in Certain Postmenopausal Women with Early Breast Cancer, Study Shows

News

Adding taselisib to Femara (letrozole) increases the measurable response in certain postmenopausal women with early breast cancer, according to a new study. The benefits were also seen in women whose tumors had ... Read more

May 11, 2017May 11, 2017

FDA Approves Kisqali Femara Co-Pack to Treat Subset of Advanced Breast Cancer Patients

News

The U.S. Food and Drug Administration (FDA) has approved Novartis Oncology‘s Kisqali Femara Co-Pack for to treat postmenopausal women with hormone receptor-positive, HER2-negative (HR+/HER2-) advanced or metastatic breast cancer. The Co-Pack, which includes Kisqali ... Read more